Sunday, June 7, 2015

Full Speed Ahead_Pfizer CEO Ian Read To Confirm Peregrine Pharmaceuticals (PPHM) Buyout Negotiations In Coming Official PR Forecasts Sierra World Equity Review

HEADLINE: Full Speed Ahead_Pfizer CEO Ian Read To Confirm Peregrine Pharmaceuticals (PPHM) Buyout Negotiations In Coming Official PR Forecasts Sierra World Equity Review. Look for the official news, when it breaks remember Sierra called this first!

Many of our publisher picks rise 100%, 200% or more once they hit the front page of our blog. Get some, sit back and enjoy the ride! Past big winners include BSTO, XCLL, HHSE, UAPC, AEMD, XTRN, RGMI, PPCH, TSGL, GNPT, RCGP, IHSI, MLER, SCRH and PCFTF and AXMP rose over 140% in just a few days!

Follow Sierra on Twitter To Get The Next Publisher Pick~~Follow Sierra on Twitter

Our New Publisher Pick Is Arrayit Corporation (ARYC). Currently the most undervalued biotech stock, with FDA approval in the pipeline, the company is working on the commercialization of it's proprietary diagnostic test for the early detection of Ovarian Cancer OvaDx® and reaching out to big pharma suitors for partnership in accelerating FDA approval of it's Parkinson’s Diagnostic Test Arrayit PDx.™ Incredibly nearly EVERY MAJOR RESEARCH CENTER IN THE WORLD uses their products even the FDA now may be a customer, the USDA loves their detection technologies for the Norovirus and Foodborne pathogens. With a  6 month price target of 60 cents but currently trading under a penny this stock has the potential to be a life changer. Don't miss out NOW is the time to buy!

With over 1.4 million visitors to our blogs and thousands of visitors daily, Sierra World Equity Review will be giving MASSIVE MULTIPLE DAY targeted audience exposure to our latest Publisher Alert: Arrayit Corporation (ARYC).

Here is why our Publisher has initiated a  position in Arrayit Corporation (ARYC)


Arrayit Corporation (ARYC) technology now allows all 25,000 human genes and every major protein in the human body to be analyzed in a few hours! (This will not be a penny stock for long, expect an uplisting to a senior exchange sooner than later)

Arrayit Corporation (ARYC) technology now allows VIP™ microarrays to enable the analysis of the DNA from 100,000 patients in one day! (Once again, it's hard to believe just how undervalued this stock currently is, expect the market to catch up soon!)

FDA approval in the pipeline: Arrayit Corporation (ARYC) has leveraged its proprietary life sciences platform to develop OvaDx®, the first definitive diagnostic screening test for early stage detection of Ovarian Cancer
Arrayit also has pipeline diagnostic tests for Parkinson’s Disease, Plavix®, Male Fertility, and Prostate Cancer. These microarray-based tests will be available to the public upon FDA approval

A new HIV & Hepatitis test that uses Arrayit Corporation (ARYC) technology is completed in only 5 minutes! (That is amazing and CUTTING EDGE technology, even big pharmas do not have this!) 

Arrayit Corporation (ARYC) has leveraged the company’s patented and proprietary microarray discovery platform to decipher the molecular basis of Parkinson’s Disease (PD). This important research project offers exciting promise for the pre-symptomatic and post-symptomatic diagnosis and treatment of this serious neurodegenerative condition. Arrayit is currently seeking a strategic partner to accelerate FDA approval of the Arrayit PDx™ Parkinson’s Diagnostic Test, speed the benchmarking of PDx™ as a companion diagnostic, and determine and enhance the efficacy of pipeline therapeutic proteins and small molecules

Arrayit Corporation (ARYC) reports microarray printer inquiry from the United States Food and Drug Administration FDA. ARYC supplies the world's top agencies!! (when the FDA wants to order your products that is HUGE!!)

Arrayit Corporation (ARYC) microarray technology is being used in search of neurological disorder cures, human stem cells arrays.

May 29th 2015..Arrayit Corporation (ARYC) announced the successful presentation of it's proprietary diagnostic test for the early detection of ovarian cancer OvaDx®, and one-on-one meetings at Marcum Microcapin Manhattan!!..(Institutional investing coming along with upgrade to a senior exchange, watch out this biotech is about to skyrocket!) 

May 17th 2015 Arrayit Corporation (ARYC) announced that because of it's ongoing Cooperative Research and Development Agreement with the United States Department of Agriculture (USDA) in the field of "Rapid and Cost Effective Detection Technologies for Noroviruses and other Foodborne Pathogens," it had the exclusive license to commercialize the technology.
Much of the food consumed in the United States, including 50% of the produce the US consumes during the winter months, is grown outside of the country. Arrayit and the USDA are expanding their food safety testing patent filings worldwide to include key food producing nations including Brazil, Canada, China, the European Union, Mexico and Peru.
Arrayit Corporation (ARYC) and the USDA Agricultural Research Service (ARS) have developed a rapid, portable, cost-effective and high-throughput detection system for the surveillance of multiple bacterial and viral foodborne pathogens including Campylobacter, E. coli, hepatitis, Listeria, norovirus and Salmonella. Expanding the USDA's patent protection will allow commercial licensing opportunities for Arrayit Corporation (ARYC) in jurisdictions worldwide.

May 14 2015 Arrayit Corporation (ARYC) Arrayit reports patented printing technology sale to a leading research institution in Ontario Canada as 4,200+ installations drive revenue!

May 13, 2015  Arrayit Corporation (ARYC) announced an agreement to supply custom Arrayit blood card technology to Vivos' Global Genome Vault, the only private human DNA vault on earth.

April 15th 2015  Arrayit Corporation (ARYC) focusing on the commercialization of it's proprietary diagnostic test for the early detection of ovarian cancer called OvaDx®, announced that it has engaged the professional services of DOCRO, Inc. to manage the preparation and the submission of the pre-submission package for OvaDx® and to conduct the negotiation with the U.S. Food and Drug Administration (“FDA”) office for the process for obtaining a 510(k) clearance of the OvaDx® device intended for use as an aid in monitoring women diagnosed with ovarian cancer.
Gregg Linn, Avant’s President and Chief Executive Officer, noted, “I am thrilled finally to reach this milestone. Since I joined the company almost 2½ years ago, my goal was simply to take OvaDx® through the FDA submission process for ovarian cancer monitoring, seek FDA clearance, and most importantly, save lives.”

As of March 31, 2015, Arrayit Corporation (ARYC) owned an equity interest in Avant Diagnostics, Inc. through ownership of 41.7% 
Arrayit Corporation (ARYC) has been featured on the hit public broadcasting TV documentary show NOVA

Nearly every major research center in the world uses Arrayit Corporation (ARYC) products including research laboratories, pharmaceutical companies, universities, biotechnology companies, hospitals, government agencies, and nonprofit research organizations
Just look at the incredible array of Arrayit Corporation (ARYC) products for 2015-2016

Arrayit Corporation (ARYC) has a fantastic share structure:
-May 12th 2015 ARYC had only 64M O/S
-April 15th 2015 ARYC had a FLOAT of just 31M (this means the share price can rise very quickly)

Stock Price Target has issued ARYC a 6 month price target of 60 cents, trading near historic lows now is the time to get in on he ground floor before the market catches up!

About Arrayit Corporation (ARYC)

Arrayit Corporation is a leading life sciences company providing innovative products and services to empower scientists and clinicians to explore the human genome as well as the genomes of plants and animals. Arrayit’s worldwide business position leverages the company’s widely used patented microarray manufacturing platform and revolutionary VIP™ genotyping technology. Nearly every major research center in the world uses Arrayit products including research laboratories, pharmaceutical companies, universities, biotechnology companies, hospitals, government agencies, and nonprofit research organizations. Novel insights into the function of genes and proteins, early stage disease diagnostics, better and safer medicines, and more nutritional crop plants are some of the many aspects of human health empowered by Arrayit technology.

Arrayit microarrays are sophisticated glass substrates containing large collections of DNA and protein spots that allow all 25,000 human genes and every major protein in the human body to be analyzed in a few hoursArrayit VIP™ microarrays enable the analysis of the DNA from 100,000 patients in one day. Since 1999, Arrayit has has build a powerful portfolio of patents, trade secrets, and more than 650 life sciences products. The company was featured on the television series NOVA in 2001, received successive appointments to the Inc. 500 list in 2002 and 2003, and has received numerous local awards including the Rising Star award from the City of Sunnyvale and the Silicon Valley 50 award in 2003

With over 1.4 million visitors to our blogs and thousands of visitors daily, Sierra World Equity Review will be giving MASSIVE MULTIPLE DAY targeted audience exposure to our latest Publisher Alert: Arrayit Corporation (ARYC) the share price is only going to rise!

Follow Sierra on Twitter To Get The Next PUBLISHER ALERT~~Follow Sierra on Twitter

About Sierra World Equity Review
Every day we present our publisher's pick where we profile a stock that our publisher has taken a position in, we believe that the stock is extremely undervalued with potential for significant percentage gains. We also issue short term daily buy or sell ratings with 5 day price targets for stocks in all industries across all markets and make speculative predictions on potential joint ventures, mergers and acquisitions.

Sierra World Equity Review and it's publisher have not been compensated to promote  Arrayit Corporation (ARYC) but do hold a long position in the stock. We are not affiliated with any executives, owners, brokers, promoters or analysts. The publisher of Sierra World Equity Review is not a registered investment adviser, before making a purchase or sale of any securities featured on this site, we strongly recommend consultation with a registered securities representative. Please remember to do your own due diligence in regards to any stocks that appear on our websites, please read our disclaimer and privacy policy below.